Goldman Sachs added Biogen to its Americas Conviction List, highlighting the biotech's lead pipeline Alzheimer's drug as possibly one of the first to successfully prevent or slow the progression of the disease. "Biogen has a broad Alzheimer's disease portfolio, which, if successful, would allow it to access a greenfield, blockbuster market opportunity,"...